Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
AssigneeHutchison Health, LLC
InventorWilliam Bradley Worthington
Life of this patent
Estimating the term…
Loading patent…
AssigneeHutchison Health, LLC
InventorWilliam Bradley Worthington
Estimating the term…
Opioid-free, anesthetic, analgesic, antalgesic, anti-nociceptive, anti-inflammatory, antiemetic formulations, and methods for reducing pain, controlling pain, preventing pain, reducing or eliminating exposure to opioids, decreasing nausea and vomiting, featuring administration of the anesthetic/analgesic formulations. The opioid-free/sparing anesthetic/analgesic formulations comprise a local anesthetic, a cyclooxygenase (COX) inhibitor, and an alpha agonist. The formulations may optionally comprise additional compositions including but not limited to NMDA receptor antagonists, Buprenorphine, Dexketoprofen, Carprofen, an antifibrinolytic, an antibiotic, a steroid, a cyclooxygenase 3 inhibitor, a Transient Receptor Potential Vanilloid (TRPV) receptor agonist or antagonist, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate agonist, a glutamate or glycine inhibitor or antagonist, a neurokinin-1 receptor antagonist, an alpha agonist, a second alpha agonist, and combinations thereof. The formulations are effective for significantly reducing postoperative nausea and vomiting and enhancing postoperative pain relief as compared to existing prior art anesthetics/analgesics.
A method of treating pain, and reducing nausea and vomiting, said method comprising administering, by infiltrative means, a clinically effective amount of a formulation to a mammal in need of such treatment, the formulation comprising about 0.01%-0.5% of a local anesthetic comprising Bupivacaine Hydrochloride, about 0.01-1.5 mg/cc of a cyclooxygenase (COX) inhibitor comprising Carprofen, about 0.0001-0.05 mg/cc of an alpha agonist comprising Dexmedetomidine, and a Transient Receptor Potential channel agonist comprising Vocacapsaicin.
Dependencies are inferred from the claim text.